Cui Fangfang, Wang Wenling, Zhuang Chunbo, He Dezhi, Wang Pei
Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Academy of Medical Sciences of Zhengzhou University, Zhengzhou, China.
Transl Cancer Res. 2024 Apr 30;13(4):1606-1622. doi: 10.21037/tcr-23-2252. Epub 2024 Apr 12.
RNA-binding motif protein 39 (RBM39) is a well-known RNA-binding protein involved in tumorigenesis; however, its role in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to investigate the role of RBM39 in HCC.
The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were used to analyze the differential expression of RBM39 in HCC and normal tissues. The prognostic and diagnostic value of RBM39 in HCC was accessed by Kaplan-Meier analysis, Cox regression, and receiver operating characteristic (ROC) curve analyses. Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to validate the mRNA and protein expression of RBM39 in HCC. Moreover, gene set enrichment analysis (GSEA) was performed to identify key pathways related to RBM39. The correlation between RBM39 expression and immune cell infiltration was evaluated using a single-sample gene set enrichment analysis (ssGSEA). CCK8 and wound healing assays were performed to investigate the proliferation and migration abilities of HCC cells with RBM39 knockdown.
RBM39 expression was upregulated in the HCC tissues. High RBM39 expression was significantly associated with advanced T stage, histological grade, and pathological stage and predicted poor overall survival (OS), disease-specific survival (DSS), and progress-free interval (PFI) in HCC patients. The upregulation of RBM39 expression was an independent prognostic factor for OS. Moreover, GSEA enrichment analysis indicated that RBM39 was functionally involved in pathways associated with the cell cycle, DNA replication, the p53 signaling pathway, and primary immunodeficiency. RBM39 expression was associated with infiltration of Th2 cells and dendritic cells (DC). RBM39 knockdown significantly inhibited the proliferation and migration of HCC cells.
These findings suggest that high RBM39 expression is associated with poor prognosis and promotes HCC cell proliferation and migration. Based on these results, RBM39 is a promising prognostic biomarker with functional significance for HCC.
RNA结合基序蛋白39(RBM39)是一种参与肿瘤发生的著名RNA结合蛋白;然而,其在肝细胞癌(HCC)中的作用仍不清楚。本研究旨在探讨RBM39在HCC中的作用。
利用癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)分析RBM39在HCC和正常组织中的差异表达。通过Kaplan-Meier分析、Cox回归和受试者工作特征(ROC)曲线分析评估RBM39在HCC中的预后和诊断价值。采用定量实时聚合酶链反应(qRT-PCR)和免疫组织化学方法验证RBM39在HCC中的mRNA和蛋白表达。此外,进行基因集富集分析(GSEA)以鉴定与RBM39相关的关键通路。使用单样本基因集富集分析(ssGSEA)评估RBM39表达与免疫细胞浸润之间的相关性。进行CCK8和伤口愈合试验以研究RBM39敲低的HCC细胞的增殖和迁移能力。
RBM39在HCC组织中表达上调。RBM39高表达与晚期T分期、组织学分级和病理分期显著相关,并预测HCC患者的总生存期(OS)、疾病特异性生存期(DSS)和无进展生存期(PFI)较差。RBM39表达上调是OS的独立预后因素。此外,GSEA富集分析表明,RBM39在功能上参与了与细胞周期、DNA复制、p53信号通路和原发性免疫缺陷相关的通路。RBM39表达与Th2细胞和树突状细胞(DC)浸润相关。RBM39敲低显著抑制HCC细胞的增殖和迁移。
这些发现表明,RBM39高表达与预后不良相关,并促进HCC细胞增殖和迁移。基于这些结果,RBM39是一种有前景的预后生物标志物,对HCC具有功能意义。